Felipe de Arriba
About
Felipe de Arriba is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Felipe de Arriba has authored 71 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Hematology, 31 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Felipe de Arriba's work include Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (21 papers) and Peptidase Inhibition and Analysis (16 papers). Felipe de Arriba is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), Protein Degradation and Inhibitors (21 papers) and Peptidase Inhibition and Analysis (16 papers). Felipe de Arriba collaborates with scholars based in Spain, United Kingdom and United States. Felipe de Arriba's co-authors include Jesús F. San Miguel, Juan José Lahuerta, Javier de la Rubia, María‐Victoria Mateos, Laura Rosiñol, Joan Bladé, Albert Oriol, Miguel‐Teodoro Hernández, Anna Sureda and Bruno Paiva and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Felipe de Arriba
67 papers receiving 1.8k citations
Peers
Felipe de Arriba
K.R. Desikan United States
Shinichi Mizuno Japan
Amanda F. Cashen United States
Susan K. Atwater United States
Michel Delforge Belgium
Thomas Köhnke Germany
Bijay Nair United States
B Barlogie United States
Manoj Raghavan United Kingdom
Blanca Sánchez‐González Spain
Citations per year, relative to Felipe de Arriba Felipe de Arriba (= 1×)
peers
K.R. Desikan
Countries citing papers authored by Felipe de Arriba
Since
Specialization
Citations
This map shows the geographic impact of Felipe de Arriba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felipe de Arriba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felipe de Arriba more than expected).
Fields of papers citing papers by Felipe de Arriba
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Felipe de Arriba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felipe de Arriba. The network helps show where Felipe de Arriba may publish in the future.
Co-authorship network of co-authors of Felipe de Arriba
This figure shows the co-authorship network connecting the top 25 collaborators of Felipe de Arriba. A scholar is included among the top collaborators of Felipe de Arriba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felipe de Arriba. Felipe de Arriba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Arriba, Felipe de, et al.. (2024). Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study. Pharmaceuticals. 17(10). 1272–1272.
2.
Gironella, Mercedes, et al.. (2023). Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain. Carinae Study. Blood. 142(Supplement 1). 4694–4694.
3.
Arriba, Felipe de, et al.. (2022). How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. Cancers. 15(1). 155–155.
4.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Javier de la Rubia, et al.. (2022). Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. European Journal of Cancer. 174. 243–250.
5.
Puig, Noemí, Luís A. Corchete, Julio Dávila, et al.. (2020). Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers. 12(12). 3615–3615.
6.
Ocio, Enrique M., Paula Rodríguez‐Otero, Joaquín Martínez‐López, et al.. (2020). Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. British Journal of Haematology. 192(3). 522–530.
7.
Kaiser, Martin, Meral Beksaç, Nina Gulbrandsen, et al.. (2020). Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology. 99(8). 1793–1804.
8.
Arriba, Felipe de, Miguel Ángel Álvarez-Avitia, Marta Sonia González, et al.. (2017). Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation. Seminars in Hematology. 55(4). 189–196.
9.
Español, Ignacio, Carmen García‐Rodríguez, A. Martínez, et al.. (2017). Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement. Clinical Case Reports. 5(8). 1258–1260.
10.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2016). Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. The Lancet Oncology. 17(8). 1127–1136.
11.
Przychodzen, B, Brittney Dienes, Ana Isabel Antón, et al.. (2015). Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. Blood Cancer Journal. 5(8). e342–e342.
12.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447.
13.
Paiva, Bruno, Joaquín Martínez‐López, María‐Belén Vídriales, et al.. (2011). Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. Journal of Clinical Oncology. 29(12). 1627–1633.
14.
Arriba, Felipe de, et al.. (2011). Estudio observacional restrospectivo para evaluar la efectividad y seguridad de esquemas de tratamiento con bortezomib para el mieloma múltiple en nuestro hospital. Farmacia Hospitalaria. 36(4). 275–281.
15.
Lahuerta, Juan José, M.V. Mateos, Joaquín Martínez‐López, et al.. (2010). Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica. 95(11). 1913–1920.
16.
Lahuerta, Juan José, María‐Victoria Mateos, Joaquín Martínez‐López, et al.. (2008). Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology. 26(35). 5775–5782.
17.
Carreras, Enric, Laura Rosiñol, María José Terol, et al.. (2007). Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation. 13(12). 1448–1454.
18.
Díaz, Miguel Ángel, Marta González‐Vicent, Amparo Verdeguer, et al.. (2005). Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). Bone Marrow Transplantation. 36(9). 781–785.
19.
Rivera, José, Marı́a Luisa Lozano, Rocío Gónzález‐Conejero, et al.. (1998). A Radioreceptor Assay for Mass Measurement of Inositol (1,4,5)-Trisphosphate Using Saponin-Permeabilized Outdated Human Platelets. Analytical Biochemistry. 256(1). 117–121.
20.
Lozano, Marı́a Luisa, Francisco José Ortuño, Felipe de Arriba, et al.. (1995). Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells. Annals of Hematology. 71(3). 105–110.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by K.R. Desikan Breakdown of academic impact, for papers by Shinichi Mizuno Breakdown of academic impact, for papers by Amanda F. Cashen Breakdown of academic impact, for papers by Susan K. Atwater Breakdown of academic impact, for papers by Michel Delforge Breakdown of academic impact, for papers by Thomas Köhnke Breakdown of academic impact, for papers by Bijay Nair Breakdown of academic impact, for papers by B Barlogie Breakdown of academic impact, for papers by Manoj Raghavan Breakdown of academic impact, for papers by Blanca Sánchez‐González